title: Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy.
abstract: BACKGROUND
  Although some studies have reported a potential connection between ovulation induction therapy (OIT) and malignant ovarian diseases, the results have been inconclusive. In the present study, we sought to determine whether women undergoing OIT at our in vitro fertilization (IVF) clinic, especially those with severe ovarian hyperstimulation syndrome (OHSS) and suspicious cytologic findings, were at risk for developing malignant ovarian tumours after treatment.
  
  
  METHODS
  Patients who underwent OIT at our IVF clinic were enrolled in this study and assessed for any evidence of malignant ovarian tumours. Patients who developed severe OHSS as a result of OIT were treated with a culdocentesis. Cells from the ascitic fluid were cytologically scored for abnormality and malignancy. Peripheral blood samples were obtained from patients with severe OHSS to determine serum levels of the tumour markers (CA-125 and HE4) that were used to calculate the Risk for Ovarian Malignancy Algorithm (ROMA) index.
  
  
  RESULTS
  Follow-up data were available for 1,353 of the 1,587 patients (85%) who underwent OIT at our IVF clinic between January 2006 and December 2012. Twenty-three patients (1.4%) were hospitalized with OHSS. Culdocentesis was performed 16 times in nine patients with severe OHSS (age range, 23-34 years; mean, 27.1 years). Although cytological examination of the ascitic cells of these patients suggested malignant ovarian neoplasia, over the course of the observation period, the ovarian volume gradually decreased and became normal. Subsequent cytological and histological examinations failed to find evidence of any malignant tumours in these nine patients. None of the 1,353 participants who underwent OIT developed any malignant ovarian tumours during the study period. Moreover, none of the 462 patients who were in our ovarian tumour registry were also participants in the IVF program.
  
  
  CONCLUSIONS
  The presence of atypical cells in the ascitic fluid of women with severe OHSS does not likely indicate malignancy; therefore, radical surgical intervention is not justified. The risk of malignancy is minimal shortly after OIT. At our centre, OIT has not been associated with any cases of ovarian tumour.
authors.affiliation: Department of Obstetrics and Gynaecology, University of Pecs, Clinical Centre, Edesanyak Str, 17, 7624 Pecs, Hungary. dr.hatzipetros@yahoo.com.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Hatzipetros
authors.forename: Peter M
authors.initials: PM
authors.lastname: Gocze
authors.forename: Katalin
authors.initials: K
authors.lastname: Cziraky
authors.forename: Kalman
authors.initials: K
authors.lastname: Kovacs
authors.forename: Endre
authors.initials: E
authors.lastname: Kalman
authors.forename: Balint
authors.initials: B
authors.lastname: Farkas
mesh_terms: D000465:Algorithms; D001202:Ascitic Fluid / Q000473:pathology*; D018394:CA-125 Antigen / Q000097:blood; D003464:Culdoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000150:complications / Q000473:pathology* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000150:complications* / Q000473:pathology; D010062:Ovulation Induction / Q000009:adverse effects; D011506:Proteins / Q000378:metabolism; D018570:Risk Assessment; D000081102:WAP Four-Disulfide Core Domain Protein 2
chemical_list: D018394:CA-125 Antigen; D011506:Proteins; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human
references.citation: Acta Eur Fertil. 1992 Mar-Apr;23(2):79-84
references.pmid: 1295280
references.citation: Hum Reprod. 1993 Dec;8(12):2075-7
references.pmid: 8150905
references.citation: Am J Reprod Immunol. 2002 Dec;48(6):355-60
references.pmid: 12607771
references.citation: Am J Epidemiol. 2002 Feb 1;155(3):217-24
references.pmid: 11821246
references.citation: Reprod Biol Endocrinol. 2007 Mar 15;5:9
references.pmid: 17362511
references.citation: Fertil Steril. 1996 Jan;65(1):13-8
references.pmid: 8557128
references.citation: Am J Obstet Gynecol. 1992 Mar;166(3):853-4
references.pmid: 1550153
references.citation: Am J Epidemiol. 1998 Jun 1;147(11):1038-42
references.pmid: 9620047
references.citation: Lancet. 1993 May 22;341(8856):1346
references.pmid: 8098472
references.citation: J Exp Clin Assist Reprod. 2009 Jun 10;6:3
references.pmid: 20485578
references.citation: Semin Reprod Med. 2010 Nov;28(6):448-57
references.pmid: 21082502
references.citation: Gynecol Oncol. 2009 Jan;112(1):40-6
references.pmid: 18851871
references.citation: Fertil Steril. 2009 Nov;92(5):1586-93
references.pmid: 18930213
references.citation: Gynecol Oncol. 1995 Jul;58(1):116-9
references.pmid: 7789877
references.citation: Obstet Gynecol Int. 2012;2012:429085
references.pmid: 22496700
references.citation: Fertil Steril. 2006 Apr;85(4):819-26
references.pmid: 16580355
references.citation: Am J Epidemiol. 1992 Nov 15;136(10):1184-203
references.pmid: 1476141
references.citation: J Zhejiang Univ Sci B. 2013 May;14(5):359-71
references.pmid: 23645173
references.citation: Lancet. 1993 Apr 17;341(8851):986-8
references.pmid: 8096944
references.citation: Acta Obstet Gynecol Scand. 2004 Dec;83(12):1104-11
references.pmid: 15548140
references.citation: Hum Reprod. 1995 Mar;10(3):520-3
references.pmid: 7782425
references.citation: Fertil Steril. 2010 Jul;94(2):389-400
references.pmid: 20416867
references.citation: Hum Reprod Update. 2003 Jan-Feb;9(1):77-96
references.pmid: 12638783
references.citation: Gynecol Oncol. 1995 Mar;56(3):470-4
references.pmid: 7705689